William Ciambrone Net Worth

William Ciambrone biography

William F. Ciambrone serves as Executive Vice President - Technical Operations of the Company. Prior to this appointment, from April 2013 until August 2015, Mr. Ciambrone served as Executive Vice President, Technical Operations, at Shire plc, a global specialty biopharmaceutical company, where he was responsible for the strategy and operational management of the Global Technical Operations group. At Shire, he also served as Senior Vice President, Technical Operations, from January 2006 to April 2013. Prior to joining Shire plc, Mr. Ciambrone served as Senior Director, Quality Assurance, and later as Vice President, Quality, at Transkaryotic Therapies Inc., a rare disease-focused multiple product biotech company that was acquired by Shire in 2005. Mr. Ciambrone’s prior experience includes different roles at North Safety and Healthcare Products, a global drug, device, and safety equipment company and Mallinckrodt Nuclear Medicine. Mr. Ciambrone holds a bachelor’s degree in Biology from St. Anselm College, participated in graduate programs at both Brown University and the University of Pennsylvania’s Wharton School, and additionally holds an Executive Certificate in Management and Leadership from the MIT Sloan School of Management.

What is the salary of William Ciambrone?

As the Executive Vice President - Technical Operations of Sarepta Therapeutics Inc, the total compensation of William Ciambrone at Sarepta Therapeutics Inc is $4,345,190. There are 1 executives at Sarepta Therapeutics Inc getting paid more, with Gilmore O'Neill having the highest compensation of $5,168,110.

How old is William Ciambrone?

William Ciambrone is 56, he's been the Executive Vice President - Technical Operations of Sarepta Therapeutics Inc since 2019. There are 10 older and 6 younger executives at Sarepta Therapeutics Inc. The oldest executive at Sarepta Therapeutics Inc is Hans Wigzell, 82, who is the Independent Director.

What's William Ciambrone's mailing address?

William's mailing address filed with the SEC is 215 FIRST STREET, SUITE 415, , CAMBRIDGE, MA, 02142.

Insiders trading at Sarepta Therapeutics Inc

Over the last 12 years, insiders at Sarepta Therapeutics Inc have traded over $58,674,663 worth of Sarepta Therapeutics Inc stock and bought 827,614 units worth $49,516,406 . The most active insiders traders include John C Martin, Richard Barry, and M Kathleen Behrens. On average, Sarepta Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,737,275. The most recent stock trade was executed by Ian Michael Estepan on 30 August 2024, trading 5,985 units of SRPT stock currently worth $822,100.

What does Sarepta Therapeutics Inc do?

sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.

Sarepta Therapeutics Inc executives and stock owners

Sarepta Therapeutics Inc executives and other stock owners filed with the SEC include:

• Gilmore O'Neill,
  Executive Vice President, R&D and Chief Medical Officer
• William Ciambrone,
  Executive Vice President - Technical Operations
• David Howton,
  Executive Vice President, General Counsel, Secretary
• Alexander Cumbo,
  Executive Vice President and Chief Commercial Officer
• Douglas Ingram,
  President, Chief Executive Officer, Director
• Douglas S. Ingram,
  Pres, CEO & Director
• Dr. Gilmore O'Neill M.D.,
  Exec. Officer
• Dr. Louise Rodino-Klapac Ph.D.,
  Chief Scientific Officer and Head of R&D
• Ian Michael Estepan,
  Exec. VP & CFO
• William F. Ciambrone,
  Exec. VP of Technical Operations
• M. Kathleen Behrens,
  Independent Chairwoman of the Board
• Richard Barry,
  Independent Director
• Hans Wigzell,
  Independent Director
• Claude Nicaise,
  Independent Director
• Mary Gray,
  Independent Director
• John Martin,
  Independent Director
• Joseph Bratica,
  Interim Principal Financial and Accounting Officer
• Dr. Diane L. Berry,
  Sr. VP of Global Health Policy and Gov. & Patient Affairs
• Alison Nasisi,
  Chief People Officer & VP
• Ryan E. Brown,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Mary Jenkins,
  Sr. Mang. of Investor Relations
• Michael W Bonney,
  Director
• Ben Gil Price,
  Director
• Catherine Stehman Breen,
  SVP, Chief Medical Officer
• Jayant Aphale,
  SVP Technical Operations
• Jean Paul Kress,
  Director
• William Alden Goolsbee,
  Director
• Shamim Ruff,
  SVP, Chief Regulatory Affairs
• Sandesh Mahatme,
  EVP, CFO & CBO
• Guriqbal S. Basi,
  SVP, Chief Scientific Officer
• Michael A Jacobsen,
  VP of Finance and PAO
• Anthony Martignetti,
  
• Nishan Garabedian Christopher,
  President and CEO
• Anthony R Chase,
  Director
• John Hodgman,
  Director
• Arthur M Krieg,
  SVP, Chief Scientific Officer
• Edward M. Md Kaye,
  SVP & Chief Medical Officer
• Ian Michael Estepan,
  Chief Financial Officer
• Ryan Edward Brown,
  EVP, General Counsel
• Louise Rodino Klapac,
  Head of R&D, CSO
• Bilal Arif,
  Chief Tech Ops Officer
• Stephen Mayo,
  
• Kathryn Jean Boor,
  
• Dallan Murray,
  Chief Customer Officer